GlassScriptPhysician profile
Ria M Lim
NPI 1750573697
$7,396.16
in general payments reported to CMS, 2019-2025
55 companies · $967 in 2025
The $967 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,173 · 2020: $751 · 2021: $1,222 · 2022: $1,079 · 2023: $1,072 · 2024: $1,131 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,170.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,045.00 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $968.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $697.68 | 2019-2025 | Evenity, Prolia, Tepezza |
| Sanofi-Aventis U.S. LLC | $600.00 | 2019-2025 | |
| Glaxosmithkline, LLC. | $537.75 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $355.69 | 2019-2025 | Verquvo, Keytruda, Steglatro |
| Mannkind Corporation | $351.27 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $325.69 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.09 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Medtronic, INC. | $217.20 | 2021-2024 | Minimed 780g |
| Abbvie INC. | $203.58 | 2019-2022 | |
| Corcept Therapeutics | $180.60 | 2019-2025 | Korlym |
| Amneal Pharmaceuticals LLC | $143.87 | 2021-2025 | Unithroid |
| Dexcom, INC. | $129.36 | 2021-2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $127.22 | 2021-2025 | Recorlev, Gvoke Hypopen |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ria Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.